Terms: = Liver cancer AND MYD88, Q99836, MYD88D, 4615 AND Diagnosis
4 results:
1. Long noncoding RNA myd88 functions as a promising diagnostic biomarker in hepatocellular carcinoma.
Wang Z; Gao P; Sun W; Rehman AU; Jiang J; Xu S; Xue C; Zhu C; Qin X
Front Endocrinol (Lausanne); 2023; 14():938102. PubMed ID: 36793272
[TBL] [Abstract] [Full Text] [Related]
2. A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group.
Maqbool MG; Tam CS; Morison IM; Simpson D; Mollee P; Schneider H; Chan H; Juneja S; Harvey Y; Nath L; Hissaria P; Prince HM; Wordsworth H; Opat S; Talaulikar D
Pathology; 2020 Feb; 52(2):167-178. PubMed ID: 31902622
[TBL] [Abstract] [Full Text] [Related]
3. Long non-coding RNA myd88 promotes growth and metastasis in hepatocellular carcinoma via regulating myd88 expression through H3K27 modification.
Xu X; Yin Y; Tang J; Xie Y; Han Z; Zhang X; Liu Q; Qin X; Huang X; Sun B
Cell Death Dis; 2017 Oct; 8(10):e3124. PubMed ID: 29022910
[TBL] [Abstract] [Full Text] [Related]
4. Role of Osteopontin in liver Diseases.
Wen Y; Jeong S; Xia Q; Kong X
Int J Biol Sci; 2016; 12(9):1121-8. PubMed ID: 27570486
[TBL] [Abstract] [Full Text] [Related]
